A contract in Japan for DMS Wellness
LATEST
FACT

DMS announced DMS Wellness has signed a contract with Japanese Ritsubi for the supply of a minimum 400 Cellis devices over the next three years.


ANALYSIS

As a reminder, Cellis is the group’s cellulite and lymphatic drainage solution, part of the Wellness division. The agreement should lead to 400 deliveries in the next three years. This is undoubtedly good news, with the first revenues of the Wellness division now at reach, as we wrote on 17 April and a similar agreement with Chinese JCCO. However, as we also wrote at that time, this does not hide the fact that FY17 revenues were disappointing (see our Latest dated 4 February 2017) and that the FY17 results due on 30 April are very likely to be weak. We are also not too sure why DMS does not, contrary to what was the case in the previous agreement with JCCO, give an estimate of the achievable turnover with this new distribution agreement. In any case, the news is still positive and comes at a time when DMS is finding it difficult to grow (FY17 sales down 9% on a comparable basis). Again as we stated earlier, let’s hope that this new inroad into side-segments (on top of the core radiology/bone densitometry businesses) enables the group to post a stronger top-line growth for the years to come.


IMPACT

We will not change our forecasts at this stage, since the FY17 results are due in two weeks (with a likely disappointment as earlier indicated) and also since we lack details on the contract to translate it into estimates.